Actavis, who have a major pharmaceutical set-up in Malta, is furthering its collaboration with the Pharmacy Department of the University of Malta by sponsoring the forthcoming European Association of Faculties of Pharmacy Conference to be held in Malta next month.

The Actavis Group is a leading player in the development, manufacture and sale of high-quality generic pharmaceuticals. Founded as Pharmaco in 1956, and previously operating under different names such as Balkanpharma, Pharmamed, Delta, Omega Farma and UNP, the company is now one of Europe's biggest producers of generic products and an expert supplier of pharmaceutical intellectual property. Actavis Group employs over 7,000 people in 25 countries, including 300 highly skilled employees in Malta.

As an example of the work carried out as part of the pharmacy course requirements, all fifth year students are participating at the conference and will be presenting their projects to over 100 university professors from 25 European countries.

The president-elect of the American Association of the Colleges of Pharmacy, Diane Beck, and Peter Vlasses and Mike Rouse from the Accreditation Council for Pharmacy Education will be among the participants.

The conference is also supported by Malta Enterprise, Air Malta, AstraZeneca, Servier, Colgate-Palmolive, Go Mobile, the Malta Tourism Authority, Indigo Bookshop, the Ministry of Health, the Institute of Health Care and the Faculty of Medicine and Surgery of the University of Malta.

President Edward Fenech Adami is the patron of the conference while Rector Roger Ellul Micallef is the honorary president.

The official opening will take place at the University church followed by a reception at the Palace in Valletta. All those interested in participating or in supporting this conference should contact Dr Lilian Azzopardi, e-mail lilmaz@maltanet.net or tel. 2134-4971.

Sign up to our free newsletters

Get the best updates straight to your inbox:
Please select at least one mailing list.

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.